HUMIRA and Uveitis

Humira is used to treat non-infectious Uveitis in adults and children over two years old. Humira works by reducing the inflammation.

Create Possibilities*

Create Possibilities*

HUMIRA and Uveitis

Humira is used to treat non-infectious Uveitis in adults and children over two years old. Humira. Humira works by reducing the inflammation.

What is Uveitis?

Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea). Uveitis can be serious, leading to permanent vision loss. Early diagnosis and treatment are important to prevent the complications of Uveitis.

Find out more about Uveitis

Find out more

HUMIRA Safety Information

Safety information on this website includes some of the more important information to know about HUMIRA.

How does HUMIRA work?

HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Uveitis.

Taking HUMIRA

What you need to know about taking HUMIRA, including helping you get the best out of your HUMIRA treatment.

*AbbVie medications and programmes are designed to support patients on their health journey.
References:

Mayo Clinic website https://www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734.
Health Navigator Website: https://www.healthnavigator.org.nz/health-a-z/u/uveitis/.
HUMIRA Approved Consumer Medicine Information.
HUMIRA Approved Data Sheet.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.